论文部分内容阅读
目的探讨三阴型和非三阴型乳腺癌的临床病理特征及无瘤生存率,探讨治疗三阴型乳腺癌潜在的分子标记物。方法收集和统计分析本院2008年1月至2011年1月接受的484例原发性乳腺癌患者的病例资料、临床资料和术后随访资料。随机检测40例三阴型乳腺癌和40例非三阴型乳腺癌患者乳腺中的EGFR、E-cadherin和AR表达。结果三阴型乳腺癌的发病率为19.0%;三阴型乳腺癌患者的组织学分级、病理类型较非三阴型乳腺癌患者具有显著性差异,即P<0.05;三阴型和非三阴型患者主要是浸润性导管癌,三阴型患者髓样癌的占比显著高于非三阴型患者,即P<0.05;三阴型组患者的3年内的复发率和转移率显著高于非三阴型组患者,即P<0.05;三阴型患者3年内的生存率显著低于非三阴型患者,即P<0.05;三阴型患者乳腺组织中的EGFR和E-cadherin阳性表达率显著高于非三阴型患者,AR阳性表达率显著低于非三阴型患者,即P<0.05。结论三阴型乳腺癌其具有独特的临床病理特征,其肿瘤的转移复发率和无瘤生存率均较非三阴型乳腺癌不同。EGFR、E-cadherin和AR可以做为三阴型乳腺癌治疗的潜在的分子靶点。
Objective To investigate the clinicopathological features and tumor-free survival rate of triple-negative and non-triple-negative breast cancer and to explore potential molecular markers for the treatment of triple-negative breast cancer. Methods A total of 484 cases of primary breast cancer patients admitted from January 2008 to January 2011 in our hospital were collected. The clinical data and postoperative follow-up data were collected. EGFR, E-cadherin and AR expression in mammary gland of 40 cases of triple negative breast cancer and 40 cases of non-triple negative breast cancer were detected randomly. Results The incidence of triple negative breast cancer was 19.0%. The histological grade and pathological type of triple negative breast cancer patients were significantly different from those of non-triple negative breast cancer patients (P <0.05) The proportion of medullary carcinoma in patients with triple negative type was significantly higher than that in non-triple type patients (P <0.05). The patients in triple negative group had significantly higher recurrence and metastasis rates within 3 years In non-trigeminy group, P <0.05; the survival rate of trigeminy group in 3 years was significantly lower than that in non-trigeminy group (P <0.05); the positive rate of EGFR and E-cadherin The expression rate of AR was significantly higher than that of non-triple-negative patients, and the positive rate of AR was significantly lower than that of non-triple-negative patients (P <0.05). Conclusions The triple negative breast cancer has its unique clinicopathological features. The tumor recurrence rate and tumor-free survival rate are different than non-triple-negative breast cancer. EGFR, E-cadherin and AR can be used as potential molecular targets for the treatment of triple-negative breast cancer.